McDonald's Corp vs Smith & Nephew plc — how do they compare? McDonald's Corp trades at $264.95 (market cap $190.16B), while Smith & Nephew plc trades at $30.14 (market cap $12.64B). The key difference: McDonald's Corp is far larger — about 15× Smith & Nephew plc's market cap, and McDonald's Corp pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| MCD | SNN | |
|---|---|---|
Market Cap | $190.16B | $12.64B |
Volume | 2,230,036 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $341.06 | $38.70 |
52-Week Low | $264.54 | $28.73 |
Enterprise Value | $243.87B | $15.41B |
Dividend Yield | 2.78% | 2.57% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Smith & Nephew (SNN) trades at $30.43, down 0.54% on the day, with mixed technical signals showing a neutral overall stance. The company demonstrates improving fundamentals with 2024 revenue of $5.81 billion and net income of $412 million, representing a 7.09% margin. Recent product launches including the LYNX COBLATION Wand and CORI XT robotics platform highlight ongoing innovation. Cash flow trends show strong operational performance with $987 million from operations in 2024.
SNN presents a balanced investment case with improving profitability and product innovation offset by recent earnings misses. The stock trades at reasonable valuations (P/E 21.36, P/S 2.17) with analyst consensus leaning Hold (68%). Key risks include execution challenges and competitive pressures, while catalysts include robotics expansion and wound care leadership. The $500 million buyback program supports shareholder returns.
Trailing returns across standard periods
Latest headlines on both assets
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →